Stock Events

Stock Events

Sol-Gel Technologies 

€58.50
22
+€0.50+0.86% Wednesday 19:32

Statistics

Day High
59
Day Low
56.5
52W High
76.5
52W Low
5.9
Volume
-
Avg. Volume
-
Mkt Cap
191.53M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q1 2026
Q2 2026
Next
-2.45
-1.26
-0.07
1.12
Expected EPS
-1.89199759903
Actual EPS
N/A

Financials

-35.69%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
16.53MRevenue
-5.9MNet Income

Analyst Ratings

149.86Average Price Target
The highest estimate is 216.26.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4SG.STU. It's not an investment recommendation.
NVIDIA
3
NVDA
Pfizer
3
PFE
Apple
2
AAPL
Realty Income
2
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Amneal Pharmaceuticals
AMRX
Mkt Cap6.07B
Amneal Pharmaceuticals, Inc. produces generic and specialty pharmaceutical products, including dermatological treatments, which compete with Sol-Gel's dermatology product line.
ANI Pharmaceuticals
ANIP
Mkt Cap1.64B
ANI Pharmaceuticals, Inc. develops, manufactures, and markets branded and generic prescription pharmaceuticals, in direct competition with Sol-Gel's pharmaceutical products.
Collegium Pharmaceutical
COLL
Mkt Cap766.03M
Collegium Pharmaceutical, Inc. is focused on developing and commercializing pain management and other products, competing in the same therapeutic areas as Sol-Gel.
Journey Medical
DERM
Mkt Cap221.84M
Dermira, Inc. focuses on advancing new therapies in dermatology, directly competing with Sol-Gel Technologies in the dermatological market.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, develops and markets pharmaceutical products for various therapeutic areas, including dermatology, competing with Sol-Gel's offerings.
Merck
MRK
Mkt Cap370.89B
Merck & Co., Inc. offers prescription medicines, vaccines, biologic therapies, and animal health products, including treatments in dermatology and acute pain, competing with Sol-Gel.
Pfizer
PFE
Mkt Cap162.16B
Pfizer Inc. is involved in the discovery, development, manufacture, and sale of healthcare products, including those for dermatological conditions, competing with Sol-Gel.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.37B
Teva Pharmaceutical Industries Limited specializes in generic and specialty medicines, including dermatology, directly competing with Sol-Gel's product range.

About

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
Show more...
CEO
Moshe Arkin
Employees
28
Country
Israel
ISIN
IL0011417206
WKN
000A2JDHD

Listings

STU
DE
4SG.STU
F
DE
4SG.F
XNAS
US
SLGL
BOATS
BOATS
SLGL.BOATS

0 Comments

Share your thoughts

FAQ

What is Sol-Gel Technologies stock price today?▼
The current price of 4SG.STU is €58.50 EUR — it has increased by +0.86% in the past 24 hours. Watch Sol-Gel Technologies stock price performance more closely on the chart.
What is Sol-Gel Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Sol-Gel Technologies stocks are traded under the ticker 4SG.STU.
Is Sol-Gel Technologies stock price growing?▼
4SG.STU stock has fallen by -1.68% compared to the previous week, the month change is a -18.75% fall, over the last year Sol-Gel Technologies has showed a +891.53% increase.
What is Sol-Gel Technologies market cap?▼
Today Sol-Gel Technologies has the market capitalization of 191.53M
When is the next Sol-Gel Technologies earnings date?▼
Sol-Gel Technologies is going to release the next earnings report on November 05, 2026.
What were Sol-Gel Technologies earnings last quarter?▼
4SG.STU earnings for the last quarter are -0.97 EUR per share, whereas the estimation was -2.02 EUR resulting in a +52.12% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Sol-Gel Technologies revenue for the last year?▼
Sol-Gel Technologies revenue for the last year amounts to 16.53M EUR.
What is Sol-Gel Technologies net income for the last year?▼
4SG.STU net income for the last year is -5.9M EUR.
How many employees does Sol-Gel Technologies have?▼
As of September 10, 2026, the company has 28 employees.
In which sector is Sol-Gel Technologies located?▼
Sol-Gel Technologies operates in the Health & Wellness sector.
When did Sol-Gel Technologies complete a stock split?▼
The last stock split for Sol-Gel Technologies was on May 05, 2025 with a ratio of 1:10.
Where is Sol-Gel Technologies headquartered?▼
Sol-Gel Technologies is headquartered in Ness Ziona, Israel.